A PK Study of IkT-148009 in Older and Elderly Healthy Subjects
Status:
COMPLETED
Trial end date:
2024-08-27
Target enrollment:
Participant gender:
Summary
This is a two-part study. Part A consists of two different IkT-148009-201 solid dosage formulations that are being evaluated to determine their steady-state pharmacokinetic profile.
Part B is a drug-drug interaction (DDI) study focused on evaluating the impact of a strong CYP3A inhibitor on the preferred dosage determined in part A.